FTC probes Epic Systems over data access for 280 million patients

The Federal Trade Commission has opened an antitrust investigation into Epic Systems, the electronic health records company holding medical data for hundreds of millions of Americans, two people familiar with the matter said.

The FTC has sent investigative demands to others in the health technology industry seeking information about how Epic grants or withholds data access, the people said. A spokesperson for the FTC declined to comment, and Epic did not immediately respond to a request for comment.

Epic runs the patient web portal MyChart along with other electronic health record systems. Its products are used by healthcare providers that collectively treat more than 280 million people in the U.S., according to the company's website. The privately held company, headquartered in Wisconsin, already faces lawsuits brought by the state of Texas and by competitor Particle Health accusing it of shutting out rivals.

The probe threatens to reshape competitive dynamics in the electronic health records market, where Epic's dominance has drawn scrutiny from regulators and rivals. If the FTC finds Epic improperly restricts data access, it could open the market to competitors and force changes to how the company's software interoperates with outside systems.

Epic has denied the allegations, saying in court documents that its products are interoperable with outside systems and that its healthcare provider customers, not Epic, control access to patient records.

What the probe means for the EHR market

The investigation marks the latest escalation of regulatory pressure on the company that dominates the U.S. electronic health records market. Epic's MyChart portal has become a standard interface for millions of patients, giving the company a central role in how medical data flows between providers, insurers and patients.

The outcome could have broad implications for the healthcare technology sector. Rival electronic health records vendors and health data platforms stand to benefit if the FTC's probe leads to changes in how Epic manages data access. Conversely, a finding that Epic acted properly could reinforce its market position.

For healthcare providers, the stakes are high. Many hospitals and health systems have built their operations around Epic's software, and any mandated changes to data-sharing practices could affect how they exchange patient information with other providers and technology partners.

The FTC's investigative demands to other health technology companies suggest the agency is examining not just Epic's conduct but the broader structure of data access in the industry. Regulators have increasingly focused on data monopolies in healthcare, where consolidation and proprietary systems can limit patient choice and innovation.

The probe also carries implications for investor sentiment in healthcare IT. As a privately held company, Epic does not trade publicly, but the investigation could weigh on valuations across the sector if it signals broader regulatory scrutiny of how health data platforms control access to patient information. Publicly traded rivals and health data companies could face questions from investors about their own data-sharing practices.

The investigation comes as antitrust enforcement in healthcare technology has intensified, with regulators examining how dominant platforms use their control over data and infrastructure to entrench market position. The FTC's demands to other health technology companies indicate the agency is building a broader picture of data access practices across the industry, rather than focusing solely on Epic's conduct.

What happens next depends on the scope of the FTC's investigation. If the agency issues a formal complaint, Epic could face a lengthy legal battle similar to other antitrust cases in the technology sector. If the investigation closes without action, it would remove a cloud hanging over the company's market position. Either way, the probe is likely to keep data access and interoperability at the center of healthcare technology policy for the foreseeable future.

This article is for informational purposes only and does not constitute investment advice.